

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has comple⦠read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
$16.59
Price-3.46%
-$0.59
$1.176b
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$121.159m
+22.7%
1y CAGR-119.6%
3y CAGR-54.1%
5y CAGR-$2.02
+25.2%
1y CAGR-175.7%
3y CAGR-153.1%
5y CAGR-$220.478m
$185.706m
Assets$406.184m
Liabilities$191.609m
Debt103.2%
-1.7x
Debt to EBITDA-$105.323m
+29.3%
1y CAGR-28.5%
3y CAGR-16.0%
5y CAGR